Theranostic Potential of Nonoxido VIV: Lysosome-Targeted Anticancer Metallodrugs

Abstract

Cancer is a leading cause of death worldwide, posing a significant challenge to achieving the goal of ensuring healthy lives and promoting well-being for all at all ages. Cisplatin, one of the most commonly used chemotherapy drugs since its discovery, has played a pivotal role in cancer therapy. However, its use is often limited by severe side effects that can compromise the well-being of patients. However, recent studies have shown that beyond their potential for cancer treatment, metal-based drugs also have fluorescence imaging capabilities for diagnostic imaging1-2 . This allows them to serve as “theranostic” agents through the supply of therapeutic drugs and diagnostic imaging agents at the same time. The present study investigates the theranostic activity of nonoxido VIV as lysosome-targeted anticancer metallodrugs. In addition, the biomolecular (DNA/HSA) interaction of the complexes was evaluated, and they exhibit significant binding activity. Overall, it summarizes the study of non-oxidovanadium(IV)-based complexes as having fascinating potential in terms of multifunctional theranostic actions that combine the imaging and anticancer capabilities of metallodrugs. The positive results of this study2 give us great motivation to continue our research into the potential use of non-oxovanadium(IV) species for the development of anticancer metallodrugs in the near future.